How to treat localized Hodgkin lymphoma?

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Early-stage classical Hodgkin lymphoma management involves conventional chemotherapy and radiotherapy.
• Immunotherapies and novel prognostic markers are emerging as important factors.

Purpose of the Study:

• To review current knowledge on early-stage classical Hodgkin lymphoma management.
• Focus on conventional strategies, immunotherapy integration, and novel prognostic markers.

Main Methods:

• Review of current literature and clinical trial data.
• Analysis of long-term outcomes for combined modality treatments.
• Evaluation of novel agents like Brentuximab Vedotin and checkpoint inhibitors.

Main Results:

• Combined modality treatment improves progression-free survival compared to chemotherapy alone.
• Novel agents show promising results in first-line treatment.
• Interim PET-scan has limited prognostic value; role with immunotherapies is unclear.
• Metabolic tumor volume and circulating tumor DNA are emerging prognostic markers.

Conclusions:

• Immunotherapies are poised to transform front-line management of early-stage classical Hodgkin lymphoma.
• Long-term efficacy and safety data for novel agents are required.
• New prognostic markers may guide treatment decisions but require further validation for clinical use.